Metagenomi (NASDAQ:MGX) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Metagenomi (NASDAQ:MGX) in a report issued on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $10.00 price target on the stock.

Other analysts also recently issued research reports about the company. BMO Capital Markets initiated coverage on Metagenomi in a research note on Tuesday, March 5th. They set an outperform rating and a $22.00 price target for the company. Chardan Capital reissued a buy rating and issued a $21.00 price target on shares of Metagenomi in a research report on Thursday, March 28th. Jefferies Financial Group initiated coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set a buy rating and a $23.00 price objective for the company. TD Cowen assumed coverage on shares of Metagenomi in a report on Tuesday, March 5th. They issued an outperform rating on the stock. Finally, Wells Fargo & Company started coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set an overweight rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Metagenomi presently has an average rating of Moderate Buy and a consensus target price of $17.83.

Metagenomi Price Performance

Shares of NASDAQ:MGX opened at $6.46 on Tuesday. Metagenomi has a 1 year low of $5.50 and a 1 year high of $12.74. The stock has a fifty day simple moving average of $9.65.

Insider Activity at Metagenomi

In related news, major shareholder Holdings A/S Novo bought 800,000 shares of Metagenomi stock in a transaction that occurred on Tuesday, February 13th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $12,000,000.00. Following the completion of the purchase, the insider now owns 1,739,175 shares in the company, valued at $26,087,625. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.